NCITA is supporting an initial portfolio of eight Exemplar projects to demonstrate the effectiveness of the NCITA infrastructure in accelerating the validation and clinical translation of cancer imaging biomarkers.
NCITA leaders work closely with the Cancer Research UK Commercial Partnerships team to establish the best commercial model to ensure new discoveries arising from the Exemplar projects and other projects supported by Cancer Research UK become available to patients with cancer.
Investigation of short-chain fatty acid uptake in solid tumours by [
18F] fluoropivalate (FPIA) PET and its relationship with tumour proliferation in GLIOMA and other cancers
Validation of hyperpolarised [1,4-
2] fumarate as a candidate for prognostic and treatment response marker for RENAL cancer
Establishing the environment for UK multicentre clinical evaluation of whole-body (WB) MRI as a diagnostic and treatment response marker in MULTIPLE MYELOMA
Establishing the multi-platform Feasibility of Oxygen enhAnced MRI for adaptive radiotherapy planning in non-small cell LUNG CANCER
Feasibility of HER2 radionuclide imaging for stratification of BREAST CANCER patients for HER2 directed antibody-drug conjugate therapy
18F-FDOPA PET imaging in GLIOMA: feasibility study for PET guided brain biopsy